- Aimmune Therapeutics (NASDAQ:AIMT) initiated with Outperform rating and $64 (76% upside) price target by Robert Baird.
- Bluebird bio (NASDAQ:BLUE) initiated with Market Perform rating by Oppenheimer.
- Kura Oncology (NASDAQ:KURA) initiated with Outperform rating and $19 (33% upside) price target by Wedbush.
- La Jolla Pharmaceutical (NASDAQ:LJPC) initiated with Buy rating and $62 (130% upside) price target by H.C. Wainwright.
- Mustang Bio (NASDAQ:MBIO) initiated with Outperform rating and $18 (64% upside) price target by Oppenheimer.
- Mirati Therapeutics (NASDAQ:MRTX) initiated with Outperform rating by Cowen and Company.
- TrovaGene (NASDAQ:TROV) initiated with Buy rating and $1 (300% upside) price target by H.C. Wainwright. Shares up 8% premarket on robust volume.
- Rigel Pharmaceuticals (NASDAQ:RIGL) resumed with Overweight rating and $6 (79% upside) price target by Piper Jaffray.
- Cardiovascular Systems (NASDAQ:CSII) resumed with Market Perform rating by William Blair.
- Axovant Sciences (NASDAQ:AXON) downgraded to Hold with a $6 (15% upside) price target by Jefferies. Shares down 6% premarket on light volume.
- Now read: Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies
Original article